Epigenetic therapy with decitabine for myelodysplasia and leukemia.

about

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

Item

http://www.wikidata.org/entity/Q36429559

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@ast

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@en

type

Item

label

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@ast

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@en

prefLabel

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@ast

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@en

P1476

Epigenetic therapy with decitabine for myelodysplasia and leukemia.

@en

P2093

M Lübert

http://www.w3.org/2001/XMLSchema#string

P Wijermans

http://www.w3.org/2001/XMLSchema#string

P2860

Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia

Histone and chromatin cross-talk

Gene silencing in cancer in association with promoter hypermethylation

Hypomethylation distinguishes genes of some human cancers from their normal counterparts

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.

Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.

P304

585-591

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14796694.1.5.585

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16556035

http://www.w3.org/2001/XMLSchema#string